Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

A study published in the New England Journal of Medicine in June 2026 investigated the use of a combination of enfortumab vedotin and pembrolizumab in the perioperative period in patients with bladder cancer. Enfortumab vedotin is a targeted drug that binds to cancer cells, while pembrolizumab is an immunotherapy that enhances the patient's immune system. Perioperative administration means giving drugs before, during, and after surgery. The goal of this approach is to improve treatment outcomes and reduce the risk of disease recurrence. The combination of these two drugs represents a new strategy in the treatment of bladder cancer. The research was published in a prestigious medical journal.